Clinical Trial Update: Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial from Chipscreen Biosciences assesses safety, pharmacokinetics, and preliminary efficacy of CS231295 in adults with advanced solid tumors, includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Small Cell Lung Cancer

Drugs mentioned

• CS231295

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Neoplasms, Glioblastoma, Adult | Phase 1 | Status: RECRUITING